A Cost-Utility Analysis of the Risk Model-Guided Antiemetic Prophylaxis Versus Physician's Choice in Patients Receiving Chemotherapy for Early-Stage Breast Cancer- A Net-Benefit Regression Approach
Abstract
Authors
K Thavorn L Vandermeer S Mazzarello Z Wang M Clemons